niclosamide (DWRX2003) / Daewoong Pharma  >>  Phase 1
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
niclosamide (DWRX2003) / Daewoong Pharma
NCT04524052: To Evaluate Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of DWRX2003 Against COVID-19

Not yet recruiting
1
32
NA
DWRX2003, Placebo
Daewoong Pharmaceutical Co. LTD.
Healthy
12/20
12/20
NCT04592835: To Evaluate the Safety, Tolerability and Pharmacokinetic Properties of DWRX2003

Not yet recruiting
1
24
NA
DWRX2003
Daewoong Pharmaceutical Co. LTD., Novotech (Australia) Pty Limited
COVID-19 Patients
12/20
06/21
NCT04541485: To Evaluate Safety, Tolerability and Pharmacodynamics of DWRX2003 Against COVID-19 (in Philippines)

Terminated
1
2
RoW
DWRX2003, Placebo
Daewoong Pharmaceutical Co. LTD.
COVID-19 Patients
03/21
03/21
NCT04749173: To Assess the Safety, Tolerability and Pharmacokinetic Properties of Niclosamide Injectable (DWRX2003) Which is the Treatment of COVID-19 in Healthy Volunteers.

Completed
1
24
RoW
DWRX2003, 96mg, DWRX2003, 432mg, DWRX2003, 144mg
Daewoong Pharmaceutical Co. LTD.
Covid19
06/21
06/21

Download Options